Salute e Benessere

Clario presents a three-part webinar series on oncology trial solutions

Part two will present research from Clario's eCOA science team, testing accessibility functionality such as zoom-in and zoom-out capabilities in the user interface, assessing the impact of these features on data integrity in both oncology and non-oncology trials. Part two will present research from Clario's eCOA science team, testing accessibility functionality such as zoom-in and zoom-out capabilities in the user interface, assessing the impact of these features on data integrity in both...
PR Newswire
31/10/2023

Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of…

Seed financing will drive commercial growth for Cambrium's first product, NovaColl™, and accelerate expansion into new industries The Berlin-based company brings novel molecules with previously unseen functionalities to life, through a technology platform which combines biology and machine learning to supercharge product innovation. With its new class of sustainable, high-performance molecules, Cambrium is transforming the paradigm of toxic petrochemicals and unethical animal ingredients...
Nasdaq GlobeNewswire
31/10/2023

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, materially reducing current payables LONDON and NEW YORK, Oct.31, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), a clinical stage biopharmaceutical company developing innovative...
Nasdaq GlobeNewswire
31/10/2023

Gaining Popularity for Holistic Health Benefits, Global Glutathione Sales Set to…

As per the latest report, the worldwide glutathione market value is expected to rise from US$ 359.0 millionin 2023 to US$ 845.0 millionby 2033. Over the forecast period, global glutathione demand will increase at a CAGR of 8.2%. As per the latest report, the worldwide glutathione market value is expected to rise from US$ 359.0 millionin 2023 to US$ 845.0 millionby 2033. Over the forecast period, global glutathione demand will increase at a CAGR of 8.2%. Request a sample report to...
PR Newswire
31/10/2023

King Faisal Specialist Hospital and Research Centre Utilizes Early Cancer…

This groundbreaking method is distinguished by its ability to detect approximately 50 genes associated with cancer and over 3,000 genetic mutations. This represents a pivotal advancement in patient care, eliminating the need to extract tissue from the affected area for examination. This transformative step greatly enhances healthcare outcomes and elevates the overall patient experience.Liquid biopsy offers advantages over traditional tissue biopsies. It's less invasive, involving a simple...
Nasdaq GlobeNewswire
31/10/2023

TATAA Announces Formation of Scientific Advisory Board

Binodh DeSilvaDr. DeSilva is a seasoned senior healthcare industry executive with over 25 years of experience. She brings specialized expertise across the entire drug discovery and development continuum and has held leadership roles at Ultragenyx, Bristol-Myers Squibb, and Amgen. Dr. DeSilva holds a PhD in Bioanalytical Chemistry. Dr. DeSilva formerly served as the president of the American Association for Pharmaceutical Sciences and has authored multiple industry guidelines for bioanalysis. ...
PR Newswire
31/10/2023

Select the Right Medical-Grade TPU：ICP DAS - BMP Launches a New TPU Series at…

On display are Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series). All TPU series are made in Taiwan, and available in various colors, radiopaque fillers (Tungsten/Barium Sulfate), and hardness levels. We also accept small order quantities, ranging from 50 to 100 kilograms, providing flexibility for customer-specific needs in the early stages of product development. On display are Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series). All TPU...
PR Newswire
31/10/2023

iOnctura announces FDA clearance of IND application for roginolisib, a…

As the first novel allosteric modulator of PI3Kδ, roginolisib marks a new era in drug development within the class. The unique binding mode, combined with high selectivity for PI3Kδ, is expected to translate to an improved safety and tolerability profile relative to that of earlier generation inhibitors. As the first novel allosteric modulator of PI3Kδ, roginolisib marks a new era in drug development within the class. The unique binding mode, combined with high selectivity for PI3Kδ, is...
PR Newswire
31/10/2023

Leucid Bio to Participate in Upcoming Healthcare Conferences

Leucid Bio is a biotechnology company developing novel, Lateral CAR cell therapies for the treatment of refractory cancers. Leucid was established to translate 20 years of King's College London research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Leucid is headquartered in London, UK, with operations based at Guy's Hospital, which enables the Company to maintain its patient-centric focus on developing next-generation cell…
PR Newswire
31/10/2023

iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding…

For immediate release iSTAR Medical conducts first MINIject® surgeries in Ireland, expanding commercial rollout in EuropeWAVRE, Belgium — 31 October 2023 :iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces that the first patients in Ireland have been implanted withMINIject®, expanding the commercial rollout of the Company's minimally-invasive glaucoma surgery (MIGS) device across Europe.Glaucoma is the leading cause...
Nasdaq GlobeNewswire
31/10/2023

Neteera raises an additional $6.7M Series B Extension

The funds of this extension round will be used to expedite production, meet the increasing demand for Neteera's platform, and to recruit more installation and deployment personnel. This significant step will allow Neteera to further solidify its leadership in the contactless patient monitoring market. Partnering with Foxconn Technology Group, the world's leading company and powerhouse in the electronics manufacturing market, will further boost Neteera's international growth...
PR Newswire
31/10/2023

Groupe Casino: Third Quarter 2023

Third Quarter 2023 Group net sales down -5.5% as reported and -5.3% on a same-store basis France Retail sales were down -5.6% on a same-store basis, reflecting: The effect of price readjustment measures in Supermarkets/Hypermarkets taken in Q1.The commercial turnaround in historic supermarkets is confirmed, with customer traffic and volumes now positive 1at +8% and +3% respectively in 4H, while hypermarkets are seeing a gradual improvement in customer traffic Growth...
Nasdaq GlobeNewswire
31/10/2023

Basilea announces exclusive license and option agreement for potential…

Exclusive license to evaluate tonabacase in preclinical studiesExclusive option to license tonabacase at pre-agreed termsAd hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, October 31, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company, committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive evaluation license and option...
Nasdaq GlobeNewswire
31/10/2023

Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in…

Patients in the INITIUM study are taking longer than expected to experience cancer progression. Reaching the number of progressing patients required for readout may take several months or even years, which has justified an amendment of the study protocol.The amended protocol in INITIUM enables the data analysis to start mid-January 2024 after the last enrolled patient has been followed up for 18 months. The topline results from the randomized Phase II study are expected to be announced...
Nasdaq GlobeNewswire
31/10/2023

Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During…

Key Takeaways from the Generalized Anxiety Disorder Market Report Discover which therapies are expected to grab the major generalized anxiety disorder market share @Generalized Anxiety Disorder Market Report Generalized Anxiety Disorder Overview Generalized anxiety disorder (GAD) stands out as the most prevalent anxiety disorder in primary care settings, often accompanied by a significant burden of comorbidity, impairment, and disability. As per DelveInsight's...
PR Newswire
30/10/2023

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in…

Elevidys-treated boys aged 4-7 years with Duchenne showed an increase on the North Star Ambulatory Assessment (NSAA), a measure of motor function, compared to placebo at 52 weeks but the primary endpoint was not metFor all key pre-specified secondary functional endpoints, time to rise and 10-metre walk test across age groups, clinically meaningful and statistically significant treatment benefits were observedNo new safety signals observed, reinforcing the favourable and manageable...
Nasdaq GlobeNewswire
30/10/2023

Galapagos concludes strategic evaluation and signs letter of intent to transfer…

Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicinesAims to preserve the Jyseleca® (filgotinib) business and a significant number of positionsGalapagos plans to streamline its remaining operations and further build efficiencies Mechelen, Belgium; 30 October 2023, 21:01 CET; regulated information – inside information –Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S...
Nasdaq GlobeNewswire
30/10/2023

Eurobio Scientific - MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023

MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023Paris, le 30 octobre 2023 – 17h45Eurobio Scientific(FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médicalin vitrode spécialité, annonce avoir mis à disposition du public et déposé auprès de l'Autorité des Marchés Financiers (AMF) le 30 octobre 2023 son rapport financier semestriel au 30 juin 2023.Le rapport financier semestriel peut être consulté sur le site Internet de la société à...
Nasdaq GlobeNewswire
30/10/2023

Muscle Wasting Disorders Market Predicted to Reach USD 45.4 Billion by 2031…

Many diseases and conditions cause muscle wasting and weakness, like aging, cancer, sepsis, cachexia, denervation, inactivity, HIV-acquired immunity syndrome (AIDS), burns, chronic kidney or heart failure, unloading/microgravity, and muscular dystrophies. Many diseases and conditions cause muscle wasting and weakness, like aging, cancer, sepsis, cachexia, denervation, inactivity, HIV-acquired immunity syndrome (AIDS), burns, chronic kidney or heart failure, unloading/microgravity, and…
PR Newswire
30/10/2023

King Faisal Specialist Hospital and Research Centre Celebrates the Success of…

CAR T-cell therapy is an innovative treatment that enhances the ability of T-cells to recognize and destroy cancer cells after genetic modification in the laboratory to improve their targeting ability. This approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukemia.KFSH&RC emphasized that this innovative technology provides hope for patients with resistant leukemia and lymphoid tumors, especially those...
Nasdaq GlobeNewswire
30/10/2023

Pulsecare Medical's nsPFA clinical trial receives satisfactory short-term…

The nsPFA system from Pulsecare Medical is the world's first third generation of PFA technology to solve the above problems, which can output nanosecond high-voltage pulses with high repetition frequency. The nanosecond pulses can optimize the distribution of the therapeutic electric field, reduce muscle contraction, and improve the safety of the surgery. The nsPFA technology solves the problems of severe muscle contraction and high anesthesia requirements of μsPFA. The nsPFA procedure can be…
PR Newswire
30/10/2023

Radiation Detection, Monitoring and Safety Market size worth $ 3.9 Billion…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=336995 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=336995 Browse in-depth TOCon" Radiation Detection, Monitoring and Safety Market " 202 - Pages 126 – Tables 37 – Figures Revolutionizing Safety: Professional Market Research Report Unveils Innovations in Radiation Detection, Monitoring, and Safety Sector Today, we announce a groundbreaking...
PR Newswire
30/10/2023

Pulsecare Medical's nsPFA clinical trial receives satisfactory short-term…

The nsPFA system from Pulsecare Medical is the world's first third generation of PFA technology to solve the above problems, which can output nanosecond high-voltage pulses with high repetition frequency. The nanosecond pulses can optimize the distribution of the therapeutic electric field, reduce muscle contraction, and improve the safety of the surgery. The nsPFA technology solves the problems of severe muscle contraction and high anesthesia requirements of μsPFA. The nsPFA procedure can be…
PR Newswire
30/10/2023

King Faisal Specialist Hospital and Research Centre Seeks to Achieve…

Since its establishment, the department has produced over 25 types of radiopharmaceuticals with a production capacity exceeding 600,000 radiopharmaceutical preparations. The department continues to provide its products to over 50 specialized Saudi medical centers, aiming to achieve self-sufficiency in the field of radiopharmaceuticals in the Kingdom of Saudi Arabia.During the Global Health Exhibition that commenced yesterday in the capital city of Riyadh, where KFSH&RC participates as...
Nasdaq GlobeNewswire
30/10/2023
Altri  Comunicati